221 related articles for article (PubMed ID: 12477829)
21. A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein.
Chen Z; Zhou M; Gao X; Zhang G; Ren G; Gnanadurai CW; Fu ZF; He B
J Virol; 2013 Mar; 87(6):2986-93. PubMed ID: 23269806
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
Wanjalla CN; Faul EJ; Gomme EA; Schnell MJ
Vaccine; 2010 Dec; 29(1):130-40. PubMed ID: 20728525
[TBL] [Abstract][Full Text] [Related]
24. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
Wong SB; Siliciano RF
J Virol; 2005 Feb; 79(3):1701-12. PubMed ID: 15650195
[TBL] [Abstract][Full Text] [Related]
25. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
Perri S; Greer CE; Thudium K; Doe B; Legg H; Liu H; Romero RE; Tang Z; Bin Q; Dubensky TW; Vajdy M; Otten GR; Polo JM
J Virol; 2003 Oct; 77(19):10394-403. PubMed ID: 12970424
[TBL] [Abstract][Full Text] [Related]
26. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
Clarke DK; Cooper D; Egan MA; Hendry RM; Parks CL; Udem SA
Springer Semin Immunopathol; 2006 Nov; 28(3):239-53. PubMed ID: 16977404
[TBL] [Abstract][Full Text] [Related]
27. Effects of G-gene Deletion and Replacement on Rabies Virus Vector Gene Expression.
Sato S; Ohara S; Tsutsui K; Iijima T
PLoS One; 2015; 10(5):e0128020. PubMed ID: 26023771
[TBL] [Abstract][Full Text] [Related]
28. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
30. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
31. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.
Cooper D; Wright KJ; Calderon PC; Guo M; Nasar F; Johnson JE; Coleman JW; Lee M; Kotash C; Yurgelonis I; Natuk RJ; Hendry RM; Udem SA; Clarke DK
J Virol; 2008 Jan; 82(1):207-19. PubMed ID: 17942549
[TBL] [Abstract][Full Text] [Related]
34. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.
Foley HD; Otero M; Orenstein JM; Pomerantz RJ; Schnell MJ
J Virol; 2002 Jan; 76(1):19-31. PubMed ID: 11739668
[TBL] [Abstract][Full Text] [Related]
35. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
36. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.
Foley HD; McGettigan JP; Siler CA; Dietzschold B; Schnell MJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14680-5. PubMed ID: 11114165
[TBL] [Abstract][Full Text] [Related]
37. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
zur Megede J; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW
J Virol; 2003 Jun; 77(11):6197-207. PubMed ID: 12743276
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge.
Baliga CS; van Maanen M; Chastain M; Sutton RE
Mol Ther; 2006 Sep; 14(3):432-41. PubMed ID: 16713742
[TBL] [Abstract][Full Text] [Related]
39. Recombinant rabies virus as potential live-viral vaccines for HIV-1.
Schnell MJ; Foley HD; Siler CA; McGettigan JP; Dietzschold B; Pomerantz RJ
Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3544-9. PubMed ID: 10706640
[TBL] [Abstract][Full Text] [Related]
40. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
